# 2025年12月15日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 靶向m6A去甲基化酶ALKBH5可抑制结直肠癌的干性与化疗耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390849)
**期刊：** Nature communications
**PMID：** 41390849
**DOI：** 10.1038/s41467-025-67502-0

### 第一部分 原文与翻译

**英文原标题：** Targeting of the mA eraser ALKBH5 suppresses stemness and chemoresistance of colorectal cancer.

> **英文摘要：**
> The role of RNA N-methyladenoine (mA) eraser AlkB homologue 5 (ALKBH5) in colorectal cancer (CRC) stem cells (CSCs) is unclear. Here, we find that ALKBH5 expression positively correlates with CSC markers in CRC patients. ALKBH5 induces self-renewal and stemness markers in colorectal CSCs and patient-derived organoids (PDOs). Colon-stem cell specific Alkbh5 knockin accelerates carcinogen-induced CRC, while tumorigenesis is attenuated in colon-stem cell specific Alkbh5 knockout mice. Integrated RNA-seq, MeRIP-seq and Ribo-seq reveal FAM84A as an ALKBH5 target. ALKBH5 demethylates mA-modified FAM84A mRNA, causing mRNA decay and reduced expression. Mechanistically, we show that FAM84A represses CSCs by interacting with β-catenin and promoting β-catenin ubiquitination and degradation. By boosting CSCs, ALKBH5 overexpression elicit chemoresistance in CSCs, PDOs and transgenic mice. Targeting of ALKBH5 by knockout or VNPs-siALKBH5 synergizes with chemotherapy to trigger tumor regression in CSCs-/PDOs-derived xenografts and ALKBH5 knockout mice. Together, we reveal that ALKBH5 is essential for colorectal CSCs and is a therapeutic target for overcoming CRC chemoresistance.

> **中文摘要：**
> RNA N-甲基腺苷（m6A）去除酶AlkB同源物5（ALKBH5）在结直肠癌（CRC）癌症干细胞（CSCs）中的作用尚不明确。本研究发现，在CRC患者中，ALKBH5的表达与CSC标志物呈正相关。ALKBH5可在结直肠CSC及患者来源的类器官（PDOs）中诱导自我更新及干性标志物的表达。特异性于结肠干细胞的Alkbh5基因敲入可加速致癌物诱导的CRC发生，而在结肠干细胞特异性Alkbh5敲除小鼠中，肿瘤发生被显著减弱。综合RNA测序、MeRIP测序及Ribo测序结果揭示FAM84A是ALKBH5的靶基因。ALKBH5可去甲基化m6A修饰的FAM84A mRNA，引发mRNA降解并降低其表达。在机制上，我们发现FAM84A通过与β-连环蛋白（β-catenin）相互作用并促进其泛素化降解，从而抑制CSC特性。由于增强CSC特征，ALKBH5过表达会在CSC、PDO和转基因小鼠中诱导化疗耐药。通过敲除ALKBH5或应用VNPs-siALKBH5，可与化疗产生协同效应，诱导CSC/PDO来源的异种移植瘤及ALKBH5敲除小鼠的肿瘤回归。综上所述，我们揭示ALKBH5对于结直肠CSC至关重要，并且是克服CRC化疗耐药的重要治疗靶点。

### 第二部分 AI 大师评价

该研究聚焦于m6A去甲基化酶ALKBH5在结直肠癌干细胞中的调控作用，结合RNA-seq、MeRIP-seq与Ribo-seq等多组学手段揭示其分子机制。作者发现ALKBH5通过靶向FAM84A调控β-连环蛋白降解，从而维持癌干性与化疗耐药。功能实验验证了敲除或抑制ALKBH5可增强化疗敏感性并抑制肿瘤进展，具有较强的临床转化潜力。研究系统性揭示了m6A调控在CRC干性维持中的关键节点，创新性突出，但尚需进一步验证其在临床人群中的安全性与有效性。

---

## 2. 新冠疫情期间出生队列的父母社会经济构成发生了变化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390820)
**期刊：** Nature communications
**PMID：** 41390820
**DOI：** 10.1038/s41467-025-66264-z

### 第一部分 原文与翻译

**英文原标题：** Parental socioeconomic composition of birth cohorts changed during the COVID-19 pandemic.

> **英文摘要：**
> The COVID-19 pandemic offers opportunities to study effects of in-utero and early life exposure to environmental changes. However, inferences from such studies may be flawed if the pandemic has changed the socioeconomic composition of parents. Analysing over 77.9 million live births from 15 countries, we estimate changes in the socioeconomic composition of the cohort born between December 2020 and December 2021 using interrupted time series analysis. We find that, compared with their counterfactual compositions, the December 2020-December 2021 birth cohort has a higher proportion of babies born to socioeconomically advantaged parents in Austria, England, Finland, the Netherlands, Scotland, Spain, Wales, and the United States while we observe the opposite change for Brazil, Colombia, Ecuador, and Mexico. These changes in cohort composition may cause between-cohort differences in life course outcomes that are influenced by parental socioeconomic circumstances even if early life exposure to the pandemic had no direct effect on this birth cohort.

> **中文摘要：**
> 新冠疫情为研究胎儿期和早期生命阶段接触环境变化的影响提供了契机。然而，如果疫情改变了父母的社会经济构成，则此类研究的推论可能存在偏差。我们分析了来自15个国家的超过7790万例活产数据，利用中断时间序列分析评估了2020年12月至2021年12月出生队列社会经济构成的变化。研究发现，与其反事实构成相比，2020年12月至2021年12月的出生队列在奥地利、英格兰、芬兰、荷兰、苏格兰、西班牙、威尔士和美国拥有较高比例的来自社会经济优势家庭的婴儿，而在巴西、哥伦比亚、厄瓜多尔和墨西哥则表现出相反的变化。这些队列构成的变化可能导致不同出生队列之间的生命历程结局差异，即使早期生命期对疫情的暴露并未对该出生队列产生直接影响。

### 第二部分 AI 大师评价

本研究旨在探讨新冠疫情是否导致出生队列父母社会经济构成的变化。研究者基于15个国家超过7790万例活产数据，采用中断时间序列分析，揭示了疫情期间不同国家社会经济群体的生育变化。结果显示，部分发达国家中高社会经济地位父母的比例上升，而拉美国家出现相反趋势。该研究创新性地揭示了疫情对人口结构和长期健康研究推论的潜在影响，但其因果解释仍受限于数据的生态层面。

---

## 3. 清醒状态下呼吸增强的人脑脊液净流动

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390815)
**期刊：** Nature communications
**PMID：** 41390815
**DOI：** 10.1038/s41467-025-66548-4

### 第一部分 原文与翻译

**英文原标题：** Human cerebrospinal fluid net flow enhanced by respiration during the awake state.

> **英文摘要：**
> Cerebrospinal fluid dynamics play a crucial role in maintaining brain homeostasis by delivering nutrients, transmitting immune signals, and clearing waste products. While cardiac activity primarily drives the pulsatile movement of cerebrospinal fluid, respiration has been shown to facilitate low-frequency oscillations and contribute to bulk flow. Recent studies suggest that enhancing respiratory function may be an effective intervention to modulate cerebrospinal fluid dynamics. This study included 20 individuals with long-term formal training in Seokmun Hoheup, a lower belly-centered breathing practice (mean ± SD age, 58.1 ± 17.3 years; 8 females), and 25 controls with no formal long-term breathing practice (mean ± SD age, 49.2 ± 20.2 years; 12 females). All underwent real-time velocity-encoding magnetic resonance imaging to assess cerebrospinal fluid movement at the foramen magnum and lateral ventricle during both regular breathing and deep breathing. Deep breathing enhances cerebrospinal fluid dynamics in both groups, increasing displacement and net flow, particularly at the foramen magnum. Seokmun Hoheup trained participants show greater cerebrospinal fluid movement than controls at both the foramen magnum and lateral ventricle. Even during regular breathing, trained participants show higher cerebrospinal fluid mean speed, displacement, and net flow. Among respiratory factors, inhale length and diaphragm displacement show the strongest correlations with cerebrospinal fluid movement. Respiration modulated cerebrospinal fluid dynamics through both mechanical enhancement of venous outflow and autonomic modulation of the heart, with mechanical effects predominating in the lateral ventricle and both pathways contributing to the foramen magnum. Our findings identify respiration in the awake state as a modifiable, noninvasive mechanism that influences involuntary functions such as cerebrospinal fluid dynamics and may have implications for cerebrospinal fluid-mediated brain homeostasis.

> **中文摘要：**
> 脑脊液动力学在维持脑内稳态中发挥关键作用，通过输送营养物质、传递免疫信号并清除代谢废物。尽管心脏活动主要驱动脑脊液的搏动性流动，但研究显示呼吸能够促进低频振荡并有助于总体流动。近期研究提示，增强呼吸功能可能是一种有效的干预手段，以调节脑脊液动力学。本研究纳入了20名长期接受石门呼吸（以下腹为中心的呼吸训练）正式训练的个体（平均年龄±标准差：58.1 ± 17.3岁；女性8名）以及25名未接受正式长时间呼吸训练的对照者（平均年龄±标准差：49.2 ± 20.2岁；女性12名）。所有受试者均接受实时速度编码磁共振成像，以评估在正常呼吸和深呼吸状态下枕骨大孔及侧脑室处的脑脊液运动。结果显示，深呼吸可增强两组受试者的脑脊液动力学，增加位移和净流动，尤其在枕骨大孔处更为显著。接受石门呼吸训练的参与者在枕骨大孔和侧脑室处的脑脊液运动均高于对照组。即使在正常呼吸期间，训练组也表现出更高的脑脊液平均流速、位移和净流量。在呼吸相关因素中，吸气时间长度和膈肌位移与脑脊液运动的相关性最强。呼吸通过增强静脉回流的机械作用以及心脏的自主神经调节，共同影响脑脊液动力学，其中机械效应在侧脑室处占主导，而两种途径在枕骨大孔处均有贡献。本研究发现，清醒状态下的呼吸是一种可调节的、非侵入性的机制，能够影响脑脊液动力学等非随意生理功能，可能对脑脊液介导的脑稳态具有重要意义。

### 第二部分 AI 大师评价

本研究旨在探讨呼吸在清醒状态下对脑脊液净流动的调节作用。研究通过实时速度编码磁共振成像比较长期腹式呼吸训练者与未受训对照者的脑脊液动力学特征，结果表明深呼吸和长期呼吸训练均可显著增强脑脊液的位移与净流动。吸气时间与膈肌位移与脑脊液运动密切相关，显示呼吸通过机械与自主神经双途径调节脑脊液动力学。研究创新性地揭示了清醒状态下呼吸对脑稳态的潜在调控作用，但样本量较小及训练形式单一可能限制外推性。

---

## 4. J2单克隆抗体识别双链RNA的结构基础

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41390480)
**期刊：** Nature communications
**PMID：** 41390480
**DOI：** 10.1038/s41467-025-67414-z

### 第一部分 原文与翻译

**英文原标题：** Structural basis of double-stranded RNA recognition by the J2 monoclonal antibody.

> **英文摘要：**
> Double-stranded (ds) RNAs are major structural components of the transcriptome, hallmarks of viral infection, and primary triggers of innate immune responses. The J2 monoclonal antibody is the gold-standard method to discover and map endogenous dsRNAs across subcellular locations and cell surfaces, detect exogenous RNAs in viral infection, and surveil mRNA prophylactics and therapeutics for inflammatory dsRNAs. To define its epitope, specificity, and mechanism, we determine a 2.85 Å co-crystal structure of J2 antigen-binding fragment (Fab) bound to dsRNA. J2 uses its heavy and light chains in tandem to track the dsRNA minor groove, recognizing a staggered 8-bp duplex. J2 is highly selective for dsRNAs, requires 14 bp for robust binding, and exhibits greatly diminished binding for GC-rich dsRNAs. J2 and the R-loop-specific S9.6 antibody share a common recognition strategy distinct from intracellular dsRNA-binding proteins. This study provides mechanistic insights into dsRNA recognition and establishes a framework for reliable application and data interpretation of the J2 antibody in RNA discovery.

> **中文摘要：**
> 双链（ds）RNA是转录组的重要结构成分、病毒感染的标志以及先天免疫反应的主要触发因素。J2单克隆抗体是发现并描绘内源性双链RNA在亚细胞定位及细胞表面分布、检测病毒感染中的外源RNA，以及监测mRNA预防性和治疗性制剂中炎症相关双链RNA的金标准方法。为界定其表位、特异性及作用机制，我们解析了J2抗原结合片段（Fab）与双链RNA的2.85 Å共晶结构。J2利用其重链与轻链协同作用沿双链RNA的小沟结合，识别一个交错的8碱基对双链结构。J2对双链RNA具有高度选择性，需要14个碱基对才能实现稳定结合，并且对GC丰富的双链RNA表现出显著减弱的结合能力。J2与R环特异性抗体S9.6共享一种区别于细胞内双链RNA结合蛋白的共识识别策略。本研究揭示了双链RNA识别的分子机制，并为J2抗体在RNA发现中的可靠应用及数据解读建立了框架。

### 第二部分 AI 大师评价

该研究通过解析J2单克隆抗体与双链RNA复合物的高分辨率晶体结构，揭示了其识别双链RNA的分子基础。作者发现J2重链与轻链协同沿RNA小沟识别特定的交错双链结构，对GC含量高的双链RNA亲和力显著降低。该工作不仅阐明了J2的结合特异性与识别机制，还与S9.6抗体的策略进行了比较，提供了对外源及内源性双链RNA检测可靠性的结构学支撑。创新点在于首次从原子层面明确了J2的识别模式，但研究仍受限于晶体环境可能无法完全反映细胞内动态相互作用。

---

## 5. 应用Trilogy瓣膜进行经导管主动脉瓣植入治疗症状性原发性主动脉反流（ALIGN-AR）：一项关键的、多中心、单臂、器械豁免研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41260228)
**期刊：** Lancet (London, England)
**PMID：** 41260228
**DOI：** 10.1016/S0140-6736(25)02215-9

### 第一部分 原文与翻译

**英文原标题：** Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study.

> **英文摘要：**
> BACKGROUND: Transcatheter devices designed for calcific aortic stenosis are not optimised for use in native aortic regurgitation, and data on aortic regurgitation-dedicated platforms are limited. The extended ALIGN-AR pivotal experience with a prospectively enrolled continued-access cohort and longer follow-up aimed to characterise the safety, valve function, and clinical outcomes of transcatheter aortic valve intervention (TAVI) with a dedicated device in aortic regurgitation.
> 
> METHODS: ALIGN-AR is a prospective, multicentre, single-arm study enrolling patients at high surgical risk to undergo TAVI with a dedicated valve (Trilogy valve) for symptomatic moderate-to-severe or severe aortic regurgitation at 30 centres in the USA. Coprimary endpoints were a safety composite of major adverse events within 30 days post procedure (all-cause death, stroke, life-threatening or major bleeding, acute kidney injury, major vascular complications, need for additional surgical or percutaneous interventions, new pacemaker implantation, and moderate or greater aortic regurgitation), tested for non-inferiority against a margin of 1·35 applied to literature-based incidence of safety endpoint of 30% translating to performance goal of 40·5%, and 1-year all-cause mortality, tested for superiority against a performance goal of 25·0%. Analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT04415047), and is ongoing.
> 
> FINDINGS: Between June 8, 2018, and July 29, 2025, we screened 1352 patients and enrolled 700 patients (pivotal cohort n=180; continued access cohort n=520). Median age was 79·0 years (IQR 72·0-84·0), 321 (46%) were female, 379 (54%) were male, and 532 (76%) were White, 68 (10%) were Black or African American, and 36 (5%) were Asian. Technical success was achieved in 664 (95%) patients. The median duration of follow-up was 472 days (IQR 352-891). The 30-day primary safety composite endpoint occurred in 168 patients (24·0% [upper 97·5% CI 27·3%]; p<0·0001), meeting the performance goal. Among components of the composite safety endpoint, death occurred in 11 (1·6%), stroke in 12 (1·7%), new pacemaker implantation in 127 (21·6%) of 589, moderate aortic regurgitation in three (0·5%) of 569 and severe aortic regurgitation in none. All-cause mortality occurred in 38 at 1 year (7·7% [upper 97·5% CI 10·4%]; p<0·0001), meeting the performance goal, and in 53 (13·3%) at 2 years.
> 
> INTERPRETATION: In patients with symptomatic moderate-to-severe or severe aortic regurgitation considered to be of high surgical risk, TAVI with a dedicated platform met prespecified safety and effectiveness performance goals. We observed substantial reductions in aortic regurgitation, favourable valve haemodynamics and myocardial remodelling, with associated improvements in functional status and quality-of-life gains up to 2 years. These data support TAVI with a purpose-built device as a feasible and effective treatment option for selected patients with native aortic regurgitation who are at high risk for death or complications after surgery.
> 
> FUNDING: JenaValve Technology.

> **中文摘要：**
> 背景：为钙化性主动脉瓣狭窄设计的经导管设备并未针对原发性主动脉瓣反流进行优化，且针对主动脉瓣反流专用平台的数据较为有限。包含前瞻性持续入组队列及延长随访的ALIGN-AR关键研究旨在评估使用专用装置进行经导管主动脉瓣介入治疗（TAVI）在主动脉瓣反流患者中的安全性、瓣膜功能及临床结局。
> 
> 方法：ALIGN-AR为一项前瞻性、多中心、单臂研究，纳入在美国30家中心中接受专用Trilogy瓣膜进行TAVI治疗的高外科风险、症状性中重度或重度主动脉瓣反流患者。共同主要终点包括30天内重大不良事件的安全性复合终点（全因死亡、中风、危及生命或严重出血、急性肾损伤、重大血管并发症、需要额外外科或介入治疗、新植入起搏器以及中度或以上主动脉瓣反流），其非劣效性检验边界为1.35，对比文献报道的30%安全性事件发生率，换算为40.5%的性能目标；另一主要终点为1年全因死亡率，检验其优效性是否优于25.0%的性能目标。所有分析基于意向治疗人群进行。本研究注册号为ClinicalTrials.gov（NCT04415047），研究仍在进行中。
> 
> 结果：2018年6月8日至2025年7月29日期间，共筛查1352例患者，入组700例（关键队列180例，持续入组队列520例）。中位年龄为79.0岁（四分位距72.0–84.0），女性321例（46%），男性379例（54%），白人532例（76%），黑人或非裔美国人68例（10%），亚裔36例（5%）。技术成功率为664例（95%）。中位随访时间为472天（四分位距352–891）。30天主要安全复合终点发生于168例患者（24.0% [97.5%上置信限27.3%]；p<0.0001），达到性能目标。在复合终点的组成中，死亡11例（1.6%），中风12例（1.7%），589例中127例（21.6%）新植入起搏器，569例中3例（0.5%）出现中度主动脉反流，未见重度反流。1年全因死亡38例（7.7% [97.5%上置信限10.4%]；p<0.0001），达到性能目标；2年时53例（13.3%）。
> 
> 解释：在症状性中重度或重度主动脉瓣反流且外科手术风险较高的患者中，使用专用平台进行TAVI达到了预设的安全性和有效性性能目标。研究观察到主动脉反流显著减少、瓣膜血流动力学改善、心肌重构改善，并伴随功能状态及生活质量在2年内持续提升。研究数据支持TAVI使用专用装置作为高外科风险原发性主动脉反流患者一种可行且有效的治疗选择。
> 
> 资金支持：JenaValve Technology。

### 第二部分 AI 大师评价

本研究为ALIGN-AR关键前瞻性多中心单臂试验，评估Trilogy专用瓣膜在高外科风险主动脉瓣反流患者中的TAVI安全性与疗效。结果显示，该技术在技术成功率、短期安全终点及1年死亡率方面均达标，显著改善瓣膜血流动力学与功能状态。研究创新之处在于针对原发性主动脉瓣反流开发的专用经导管装置，填补了既有设备在该适应证下的空白。其局限在于无对照组及仍需更长期随访以验证持久效果。

---

## 6. 一种减少大型手术后中度或重度急性肾损伤的预防性护理策略（BigpAK-2）：一项多国随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41242333)
**期刊：** Lancet (London, England)
**PMID：** 41242333
**DOI：** 10.1016/S0140-6736(25)01717-9

### 第一部分 原文与翻译

**英文原标题：** A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial.

> **英文摘要：**
> BACKGROUND: Acute kidney injury (AKI) is a common and important complication of major surgery, yet recommended preventive care is rarely administered. We used urinary biomarkers to identify patients at high risk of AKI and implemented a preventive care strategy to reduce AKI within 72 h after major surgery.
> 
> METHODS: BigpAK-2 was a multicentre randomised clinical trial done in 34 hospitals in Europe. Patients (aged ≥18 years) undergoing major surgery at high risk for AKI identified by predefined clinical risk factors and tubular stress biomarkers were randomly assigned to usual care or a preventive care strategy as per recommendations by the Kidney Disease Improving Global Outcome guidelines: advanced hemodynamic monitoring, optimisation of volume status and haemodynamics, avoidance of nephrotoxic drugs and radiocontrast agents, and prevention of hyperglycaemia. The primary outcome was the occurrence of moderate or severe AKI within 72 h after surgery, assessed in the intention-to-treat population. Safety was assessed by comparing rates of adverse events between groups. This trial is registered with ClinicalTrials.gov, NCT04647396.
> 
> FINDINGS: From Nov 25, 2020, to June 21, 2024, 7873 patients were screened and 1180 (15·0%) were randomly assigned (589 [49·9%] to the intervention group and 591 [50·1%] to the control group). Among the 1176 patients available for the primary endpoint analysis, moderate or severe AKI occurred in 84 (14·4%) patients in the intervention group and in 131 (22·3%) patients in the control group (odds ratio 0·57 [95% CI 0·40-0·79; p=0·0002; number needed to treat 12 [7-33]). There were no differences in adverse events. The most common adverse events were atrial fibrillation (50 [8·8%] in the intervention group vs 56 (9·7%) in the control group), hemodynamically relevant arrhythmias (41 [7·2%] in the intervention group vs 50 [8·6%] in the control group), significant bleeding or haemorrhage (34 [6·0%] in the intervention group vs 31 [5·3%] in the control group), and unplanned return to the operating room (29 [5·1%] in the intervention vs 38 [6·5%] in the control group).
> 
> INTERPRETATION: Among adults at high risk for AKI undergoing major surgery, a preventive care strategy consisting of supportive measures and avoidance of nephrotoxins significantly reduced the occurrence of moderate or severe AKI without increasing adverse events.
> 
> FUNDING: BioMérieux.

> **中文摘要：**
> 背景：急性肾损伤（AKI）是大型手术中常见且重要的并发症，但推荐的预防性护理很少落实。本研究利用尿液生物标志物识别出AKI高风险患者，并实施了一项旨在降低术后72小时内AKI发生率的预防性护理策略。
> 
> 方法：BigpAK-2是一项在欧洲34家医院开展的多中心随机临床试验。年龄≥18岁、接受大型手术且通过预设临床风险因素和肾小管应激生物标志物被确定为AKI高风险的患者，被随机分配接受常规护理或依据《肾脏病改善全球预后指南》（KDIGO）建议的预防性护理策略，包括：高级血流动力学监测、优化容量状态与血流动力学、避免使用肾毒性药物及放射造影剂、以及预防高血糖。主要结局为术后72小时内中度或重度AKI的发生率，采用意向治疗人群进行评估。安全性通过比较两组不良事件发生率来评估。本试验注册号为ClinicalTrials.gov NCT04647396。
> 
> 结果：2020年11月25日至2024年6月21日期间，共筛查7873名患者，最终随机分配1180名（占15.0%），其中干预组589名（49.9%），对照组591名（50.1%）。在可进行主要终点分析的1176名患者中，干预组84例（14.4%）发生中度或重度AKI，对照组为131例（22.3%）（比值比0.57 [95% CI 0.40–0.79; p=0.0002]; 需治疗人数12 [7–33]）。两组不良事件无显著差异。最常见的不良事件包括心房颤动（干预组50例[8.8%] vs 对照组56例[9.7%]）、血流动力学相关心律失常（41例[7.2%] vs 50例[8.6%]）、显著出血（34例[6.0%] vs 31例[5.3%]）以及计划外再次手术（29例[5.1%] vs 38例[6.5%]）。
> 
> 解释：在接受大型手术且AKI高风险的成年患者中，采用综合支持措施与避免肾毒性因素的预防性护理策略，可显著降低中度或重度AKI的发生率，而不会增加不良事件风险。
> 
> 资金来源：BioMérieux。

### 第二部分 AI 大师评价

该研究是一项多国随机临床试验，针对大型手术后急性肾损伤的高风险人群，通过尿液生物标志物筛选并实施包括高级血流动力学监测和避免肾毒性药物在内的综合预防护理策略。结果显示，该策略在不增加不良事件的前提下显著降低了中度或重度AKI的发生率。该研究验证了KDIGO指南预防性管理的临床价值，具有较强的实践意义。其创新在于将生物标志物风险识别与系统护理干预相结合，但仍需进一步验证成本效益及广泛推广的可行性。

---

## 7. 预防急性肾损伤的综合干预措施：在支持性治疗中寻找价值

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41242331)
**期刊：** Lancet (London, England)
**PMID：** 41242331
**DOI：** 10.1016/S0140-6736(25)01964-6

### 第一部分 原文与翻译

**英文原标题：** Bundled interventions to prevent acute kidney injury: finding the value in supportive care.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该论文标题表明研究关注通过综合性干预措施预防急性肾损伤（AKI），并探讨支持性治疗的临床价值。尽管摘要未公开，但可推测文章可能强调多学科协作、标准化措施组合及优化临床流程的重要性。其创新之处可能在于重新审视基于循证医学的支持性护理策略，而非单一药物干预；局限性在于缺乏具体的研究数据，需进一步阅读原文以了解方法学与临床证据。

---

## 8. 《柳叶刀》健康与气候变化倒计时2025年度报告：应对气候变化行动为人类健康提供生命线

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41175887)
**期刊：** Lancet (London, England)
**PMID：** 41175887
**DOI：** 10.1016/S0140-6736(25)01919-1

### 第一部分 原文与翻译

**英文原标题：** The 2025 report of the Lancet Countdown on health and climate change: climate change action offers a lifeline.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本报告延续了《柳叶刀》健康与气候变化倒计时系列的传统，综合评估全球在应对气候变化对健康影响方面的进展。标题强调气候行动不仅是环境议题，更是公共卫生干预的重要途径，突出了健康系统适应与减缓措施的紧迫性。尽管暂无摘要，但推测该年度报告结合多源数据，分析政策、医疗体系与可持续发展之间的关联，为制定气候健康政策提供了新的证据基础。其创新性在于将气候行动视为挽救生命的关键动力，而局限性可能在于区域数据不平衡和模型预测的不确定性。

---

速递结束，祝您工作愉快！